by TractManager | Sep 11, 2019 | Health Technology Assessment
Health Problem: Hepatocellular carcinoma (HCC) is the most common liver malignancy in the United States, accounting for approximately 90% of primary liver cancers. The definitive therapies for HCC are surgical resection, tumor ablation, and liver transplantation;...
by TractManager | Sep 10, 2019 | Health Technology Assessment
Health Problem: In the United States, ovarian cancer ranks fifth among cancer deaths. This type of cancer is often not detected at an early stage since early signs or symptoms are usually absent or easily overlooked. There is no effective method for screening women at...
by TractManager | Sep 9, 2019 | Emerging Technology Report
Xpovio is a first-in-class oral selective inhibitor of the nuclear export protein exportin-1 (XPO1). Xpovio is believed to bind with and inhibit XPO1, causing tumor suppressor proteins to accumulate in the cell nucleus and inducing apoptosis in cancer cells while...
by TractManager | Sep 9, 2019 | Emerging Technology Report
Xpovio is a first-in-class oral selective inhibitor of the nuclear export protein exportin-1 (XPO1). Xpovio is believed to bind with and inhibit XPO1, causing tumor suppressor proteins to accumulate in the cell nucleus and inducing apoptosis in cancer cells while...
by TractManager | Sep 5, 2019 | Precision Therapy Assessment
Health Problem: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare and heterogeneous group of neoplasms derived from neuroendocrine cells within the gastrointestinal tract and pancreas, where curative surgery options are limited. GEP-NETs are estimated...
Recent Comments